Hepatic Physiology

Quick Answer

The liver is the largest solid organ (1.4-1.8 kg), receiving 25% of cardiac output through a unique dual blood supply: portal vein (75%, low O2) and hepatic artery (25%, high O2). The hepatic artery buffer response (HABR) compensates for portal flow changes, maintaining oxygen delivery. The functional unit is the hepatic acinus (Rappaport), with three metabolic zones: Zone 1 (periportal, oxidative), Zone 2 (intermediate), and Zone 3 (perivenous, reductive, vulnerable to hypoxia). The liver performs critical functions: carbohydrate metabolism (glycogenesis, gluconeogenesis, glycogenolysis), protein synthesis (albumin 12-15 g/day, clotting factors, acute phase reactants), lipid metabolism (VLDL synthesis, cholesterol regulation), ammonia detoxification (urea cycle, 20-30 g urea/day), drug metabolism (Phase I CYP450, Phase II conjugation), and bile production (500-1000 mL/day). Hepatic clearance depends on extraction ratio, hepatic blood flow, and protein binding. In critical illness, hepatic dysfunction causes coagulopathy (reduced factor synthesis), encephalopathy (hyperammonaemia, astrocyte swelling), hypoglycaemia (impaired gluconeogenesis), and altered drug handling.

---

CICM Exam Focus

What Examiners Expect

First Part Written SAQ Topics:

• Hepatic blood supply and oxygen delivery calculations
• Hepatic artery buffer response mechanism
• Hepatic acinus zones and their functional significance
• Drug metabolism phases (CYP450 system, conjugation reactions)
• First-pass effect and hepatic extraction ratio
• Bilirubin metabolism pathway (unconjugated vs conjugated)
• Ammonia metabolism and urea cycle
• Bile acid synthesis and enterohepatic circulation

First Part Viva Topics:

• Applied hepatic physiology in liver failure
• Drug dosing modifications in hepatic impairment
• Physiological basis of hepatic encephalopathy
• Portal hypertension pathophysiology
• Synthetic function assessment (albumin, coagulation factors)

Common SAQ Stems:

1. "Describe the blood supply to the liver and the hepatic artery buffer response"
2. "Explain the phases of drug metabolism in the liver and factors affecting hepatic clearance"
3. "Describe bilirubin metabolism and explain the pathophysiology of jaundice"
4. "Outline the metabolic functions of the liver relevant to intensive care"

High-Yield Calculations:

• Hepatic oxygen delivery: DO2 = (HBF × CaO2) + (Portal flow × CpvO2)
• Hepatic extraction ratio: ER = (Ca - Cv) / Ca
• Hepatic clearance: CLH = Q × ER = Q × (fu × CLint) / (Q + fu × CLint)
• MELD score: 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 9.57 × ln(creatinine) + 6.43

---

Key Points

1. Dual blood supply: Portal vein (75% flow, 50% O2) and hepatic artery (25% flow, 50% O2); total hepatic blood flow 1500 mL/min (25% cardiac output) [1,2]

2. Hepatic artery buffer response (HABR): Adenosine-mediated increase in hepatic arterial flow when portal flow decreases; maintains hepatic oxygen delivery; absent in cirrhosis [3,4]

3. Hepatic acinus (Rappaport): Functional unit organised around portal triad; Zone 1 (periportal) receives highest O2 and performs oxidative functions; Zone 3 (perivenous) receives lowest O2 and performs reductive functions, vulnerable to hypoxia [5,6]

4. Hepatocyte polarisation: Sinusoidal (basolateral) membrane faces blood; canalicular (apical) membrane faces bile canaliculi; tight junctions prevent backflow of bile [7]

5. Carbohydrate metabolism: Glycogen storage (100-120 g), gluconeogenesis (maintains fasting glucose), glycogenolysis (rapid glucose release); impaired in liver failure causing hypoglycaemia [8,9]

6. Protein synthesis: Albumin (3.5-5 g/dL, t½ 20 days), fibrinogen, prothrombin, Factors V, VII, IX, X; Factor VII t½ 6 hours (earliest marker of synthetic failure) [10,11]

7. Ammonia detoxification: Urea cycle converts ammonia to urea (20-30 g/day); failure leads to hyperammonaemia, glutamine accumulation, astrocyte swelling, cerebral oedema [12,13]

8. Drug metabolism: Phase I (CYP450 oxidation, reduction, hydrolysis) and Phase II (glucuronidation, sulfation, acetylation, glutathione conjugation); first-pass effect reduces bioavailability [14,15]

9. Hepatic extraction ratio: High ER drugs (>0.7) = flow-dependent clearance; Low ER drugs (<0.3) = capacity-dependent clearance; affects drug dosing in liver disease [16,17]

10. Bile production: 500-1000 mL/day; bile acids synthesised from cholesterol (CYP7A1); bilirubin conjugated by UGT1A1; 95% bile acids reabsorbed (enterohepatic circulation) [18,19]

---

Hepatic Blood Supply

Dual Blood Supply

The liver possesses a unique dual afferent blood supply that delivers 25% of cardiac output (approximately 1500 mL/min in a 70 kg adult). This distinctive vascular arrangement reflects the liver's dual role as a metabolic organ and filter for portal blood. [1,2]

Portal Vein:

• Provides 75% of hepatic blood flow (1000-1200 mL/min)
• Delivers 50% of hepatic oxygen supply
• Low oxygen saturation (85% SaO2, PO2 ~40 mmHg)
• Low pressure system (7-10 mmHg)
• Carries nutrient-rich blood from splanchnic circulation
• No valves; dependent on splanchnic-hepatic pressure gradient
• Formed by confluence of superior mesenteric and splenic veins
• Blood composition varies with fed/fasting state and intestinal absorption [1,20]

Hepatic Artery:

• Provides 25% of hepatic blood flow (300-400 mL/min)
• Delivers 50% of hepatic oxygen supply
• High oxygen saturation (95-100% SaO2, PO2 ~100 mmHg)
• High pressure system (mean 85-95 mmHg)
• Branch of coeliac axis (common hepatic artery)
• Autoregulates to maintain flow over MAP 60-140 mmHg
• Supplies bile ducts, portal tracts, and liver capsule
• Essential for hepatocyte viability when portal flow is compromised [2,21]

Hepatic Veins:

• Three major veins (right, middle, left) drain into IVC
• No valves; pressure reflects right atrial pressure
• Normal hepatic venous pressure gradient (HVPG) = 1-5 mmHg
• Portal hypertension defined as HVPG ≥6 mmHg; clinically significant ≥10 mmHg [22]

Total Hepatic Blood Flow

Normal Values:

• Total hepatic blood flow: 1400-1600 mL/min
• Portal vein flow: 1000-1200 mL/min (75%)
• Hepatic artery flow: 300-400 mL/min (25%)
• Flow per gram liver tissue: 0.8-1.0 mL/min/g
• Percentage of cardiac output: 25-30%

Hepatic Oxygen Delivery:

Total hepatic oxygen delivery = Arterial DO2 + Portal DO2

• Hepatic artery DO2 = 400 mL/min × 0.2 mL O2/mL blood = 80 mL O2/min
• Portal vein DO2 = 1200 mL/min × 0.14 mL O2/mL blood = 168 mL O2/min
• Total hepatic DO2 ≈ 250 mL O2/min

Hepatic Oxygen Consumption:

• Hepatic VO2: 50-60 mL O2/min (20% of total body VO2)
• Hepatic oxygen extraction: 20-25%
• Lower extraction than heart (70%) or brain (35%)
• Reserve capacity allows tolerance of moderate hypoperfusion [23,24]

Hepatic Artery Buffer Response (HABR)

The hepatic artery buffer response is a semi-reciprocal relationship whereby hepatic arterial blood flow increases when portal venous flow decreases, maintaining total hepatic blood flow and oxygen delivery. This is a unique hepatic autoregulatory mechanism. [3,4,25]

Mechanism:

1. Adenosine is continuously produced by hepatocytes and washed out by portal flow
2. When portal flow decreases, adenosine accumulates in the space of Mall (periportal area)
3. Adenosine acts on A2 receptors on hepatic artery smooth muscle
4. Vasodilation increases hepatic arterial flow
5. Compensation is approximately 25-60% of the decrease in portal flow

Characteristics:

• Response time: Seconds to minutes
• Compensation capacity: Incomplete (25-60% of portal flow decrease)
• Unidirectional: Hepatic artery does not decrease when portal flow increases
• Abolished by adenosine receptor antagonists (aminophylline, theophylline)
• Impaired in cirrhosis due to architectural distortion [26]

Clinical Relevance:

• Hepatic artery thrombosis after liver transplant → liver necrosis (no HABR protection)
• Portal vein thrombosis may be tolerated if HABR intact
• TIPS placement: Acute portal diversion triggers HABR
• Aminophylline may impair HABR via A2 receptor blockade
• Sepsis impairs HABR, contributing to ischaemic hepatitis [27]

Regulation of Hepatic Blood Flow

Intrinsic Regulation:

• HABR (adenosine-mediated)
• Myogenic response (hepatic artery only)
• Metabolic autoregulation (hepatic artery)
• Hepatic arterial pressure-flow autoregulation over MAP 60-140 mmHg [28]

Extrinsic Regulation:

Sympathetic Nervous System:

• Alpha-1 adrenoceptors on hepatic artery and portal vein
• Splanchnic vasoconstriction reduces portal inflow
• Can reduce total hepatic blood flow by 40-50%
• Activated in haemorrhage, exercise, and stress [29]

Hormonal Regulation:

• Angiotensin II: Portal and hepatic artery vasoconstriction
• Vasopressin: Splanchnic vasoconstriction, reduces portal flow
• Glucagon: Increases hepatic arterial flow and portal flow
• Catecholamines: Alpha-mediated vasoconstriction predominates
• Nitric oxide: Hepatic artery and portal venodilation [30]

Humoral Factors:

• Endothelin-1: Potent vasoconstrictor
• Prostaglandins: PGI2 vasodilation, TXA2 vasoconstriction
• Bile acids: Mild vasodilatory effect [31]

Effects of Critical Illness:

---

Liver Microanatomy

Hepatic Lobule

The classic hepatic lobule is the traditional anatomical unit of the liver, hexagonal in shape with a central vein at its centre and portal triads at each corner. [32]

Structure:

• Hexagonal shape (1-2 mm diameter)
• Central vein: Terminus of sinusoidal blood flow, drains to hepatic veins
• Portal triads at periphery: Contains portal vein branch, hepatic artery branch, bile duct
• Hepatocyte plates radiate from central vein to portal triad
• Sinusoids run between hepatocyte plates
• Bile canaliculi run between adjacent hepatocytes toward bile ducts

Limitations:

• Describes blood flow direction (portal → central)
• Does not explain metabolic zonation
• Does not predict pathological changes based on blood supply

Hepatic Acinus (Rappaport)

The hepatic acinus, described by Rappaport, is the functional unit of the liver based on blood supply and metabolic gradients. It better explains the physiological and pathological zonation of liver function. [5,6]

Structure:

• Diamond or oval-shaped region around the portal triad axis
• Blood flows from portal triad (centre) toward hepatic venules (periphery)
• Three concentric zones based on distance from portal triad:

Zone 1 (Periportal):

• Closest to portal triad blood supply
• Highest O2 content (PO2 60-70 mmHg)
• Highest nutrient concentration
• Oxidative metabolism predominates
• Functions: Gluconeogenesis, beta-oxidation, urea synthesis, cholesterol synthesis
• Most resistant to hypoxia
• First affected by toxins in portal blood
• Site of bile acid uptake and bile formation initiation [33,34]

Zone 2 (Intermediate):

• Mid-zone with intermediate O2 and nutrient levels
• Mixed oxidative and reductive functions
• Transitional metabolic phenotype
• Less studied than Zones 1 and 3

Zone 3 (Perivenous/Centrilobular):

• Closest to central (hepatic) vein
• Lowest O2 content (PO2 30-40 mmHg)
• Lowest nutrient concentration
• Reductive metabolism predominates
• Functions: Glycolysis, lipogenesis, glycogen synthesis, CYP450 biotransformation, glutamine synthesis
• Most vulnerable to hypoxia → centrilobular necrosis
• Site of drug metabolism (high CYP450 concentration)
• First affected by congestion (cardiac failure) [35,36]

Metabolic Zonation Summary:

Sinusoidal Architecture

Sinusoids:

• Unique hepatic capillaries (8-10 μm diameter)
• Fenestrated endothelium (100-200 nm pores, no diaphragm)
• Lack basement membrane → allows direct plasma-hepatocyte contact
• Blood flow: 200-300 μm/sec (slow, maximises exchange)
• Lined by sinusoidal endothelial cells (LSECs) [37,38]

Space of Disse:

• Perisinusoidal space between endothelium and hepatocytes
• Contains plasma ultrafiltrate (no blood cells)
• Site of metabolite exchange between blood and hepatocytes
• Contains hepatic stellate cells (Ito cells)
• Collagen deposition here causes capillarisation in cirrhosis [39]

Hepatic Stellate Cells (Ito Cells):

• Located in space of Disse
• Store 80% of body's vitamin A (retinol)
• Quiescent in normal liver
• Activation → myofibroblast transformation → collagen synthesis → fibrosis
• Key role in cirrhosis pathogenesis [40]

Kupffer Cells:

• Resident macrophages of the liver
• Largest population of tissue macrophages in the body
• Located within sinusoidal lumen
• Functions: Phagocytosis of bacteria, endotoxin clearance, cytokine production
• Clear 80-90% of portal vein bacteria
• Release TNF-α, IL-1, IL-6 in response to endotoxin
• Contribute to systemic inflammatory response in sepsis [41,42]

Hepatocyte Polarisation:

• Sinusoidal (basolateral) membrane: Faces blood in space of Disse
  • Uptake of nutrients, hormones, bile acids
  • Secretion of albumin, clotting factors, lipoproteins
  • Abundant transporters (NTCP, OATPs, OCTs)
• Canalicular (apical) membrane: Faces bile canaliculus
  • Secretion of bile acids (BSEP), bilirubin (MRP2), cholesterol (ABCG5/8)
  • Tight junctions seal canaliculi from blood
• Lateral membrane: Cell-cell junctions [7,43]

---

Metabolic Functions

Carbohydrate Metabolism

The liver is central to glucose homeostasis, maintaining blood glucose at 4-6 mmol/L through glycogenesis, glycogenolysis, and gluconeogenesis. Hepatic glycogen stores (100-120 g) can maintain glucose supply for 12-18 hours of fasting. [8,9,44]

Glycogenesis (Glycogen Synthesis):

• Occurs in fed state (high insulin:glucagon ratio)
• Glucose → Glucose-6-phosphate (hexokinase/glucokinase)
• G6P → Glucose-1-phosphate (phosphoglucomutase)
• G1P + UTP → UDP-glucose (UDP-glucose pyrophosphorylase)
• UDP-glucose → glycogen (glycogen synthase)
• Insulin activates glycogen synthase via dephosphorylation
• Maximum glycogen storage: 100-120 g (5-6% liver weight)
• Zone 3 hepatocytes predominate in glycogen synthesis [45]

Glycogenolysis (Glycogen Breakdown):

• Activated by glucagon, catecholamines (fasting, stress)
• Glycogen phosphorylase cleaves glucose residues
• Produces glucose-1-phosphate → glucose-6-phosphate
• Glucose-6-phosphatase (liver-specific) converts G6P → free glucose
• Released into blood for systemic use
• Provides rapid glucose release (minutes)
• Glycogen depleted after 12-18 hours fasting [46]

Gluconeogenesis:

• De novo glucose synthesis from non-carbohydrate precursors
• Precursors: Lactate (Cori cycle), pyruvate, glycerol (from TGs), amino acids (alanine, glutamine)
• Key enzymes: Pyruvate carboxylase, PEPCK, fructose-1,6-bisphosphatase, glucose-6-phosphatase
• Provides 50-60% of fasting glucose after 24 hours
• Zone 1 hepatocytes predominate
• Stimulated by glucagon, cortisol, catecholamines
• Inhibited by insulin
• Essential for fasting glucose maintenance and response to stress [47,48]

Clinical Relevance - Hypoglycaemia in Liver Failure:

• Glycogen stores exhausted (if depleted or impaired synthesis)
• Gluconeogenesis impaired (loss of hepatocyte mass)
• Reduced hepatic glucose output despite hyperglucagonaemia
• Insulin clearance reduced → hyperinsulinaemia
• Seen in acute liver failure, decompensated cirrhosis
• Requires glucose infusion (D10W at 100-150 mL/hr) [49]

Protein Synthesis

The liver synthesises the majority of plasma proteins, producing 12-15 g of albumin daily and most coagulation factors. Protein synthesis requires intact hepatocyte function, adequate amino acid substrate, and energy supply. [10,11,50]

Albumin:

• Molecular weight: 66 kDa
• Normal concentration: 35-50 g/L (3.5-5.0 g/dL)
• Half-life: 20 days
• Production: 12-15 g/day (150-250 mg/kg/day)
• Functions:
  • Oncotic pressure (75-80% of plasma oncotic pressure)
  • Transport (drugs, hormones, fatty acids, bilirubin)
  • Antioxidant (free radical scavenging)
  • Acid-base buffering
• Synthesis inhibited by: IL-6, TNF-α (negative acute phase reactant)
• Low albumin indicates chronic liver disease, not acute dysfunction
• Hypoalbuminaemia causes oedema, altered drug binding, poor prognosis [51,52]

Coagulation Factors:

• Liver synthesises all clotting factors except vWF (endothelium) and Factor VIII (liver and endothelium)
• Vitamin K-dependent factors: II, VII, IX, X, Protein C, Protein S
• Half-lives vary dramatically:

• PT/INR reflects Factor VII predominantly
• Factor V: Not vitamin K dependent, true marker of synthetic function
• Factor V <20% predicts poor outcome in acute liver failure (King's College Criteria) [53,54]

Acute Phase Reactants:

Positive Acute Phase Reactants (increase in inflammation):

• C-reactive protein (CRP): Up to 1000-fold increase
• Serum amyloid A
• Fibrinogen
• Haptoglobin
• Ceruloplasmin
• Complement components (C3, C4)
• α1-antitrypsin
• Ferritin

Negative Acute Phase Reactants (decrease in inflammation):

• Albumin
• Transferrin
• Transthyretin (prealbumin)
• Retinol-binding protein

Acute phase response is IL-6 mediated, redirecting hepatic protein synthesis toward inflammatory mediators at the expense of albumin and transport proteins. [55]

Lipid Metabolism

The liver is central to lipid homeostasis, synthesising cholesterol, triglycerides, phospholipids, and lipoproteins while also performing beta-oxidation and ketogenesis. [56,57]

Cholesterol Metabolism:

• Endogenous synthesis: 800-1000 mg/day (HMG-CoA reductase pathway)
• Dietary intake: 300-500 mg/day
• Biliary excretion: 500-600 mg/day (as cholesterol and bile acids)
• Bile acid synthesis from cholesterol (CYP7A1 rate-limiting)
• Reverse cholesterol transport via HDL
• Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis [58]

Lipoprotein Metabolism:

• VLDL synthesis: Triglyceride-rich particles secreted by hepatocytes
• LDL receptor-mediated uptake of LDL cholesterol
• HDL synthesis and maturation
• Lipoprotein lipase regulation
• ApoB-100 synthesis (essential for VLDL/LDL)
• Impaired lipoprotein synthesis in liver disease → low cholesterol (poor prognosis marker) [59]

Beta-Oxidation:

• Mitochondrial fatty acid oxidation
• Generates acetyl-CoA for TCA cycle or ketogenesis
• Occurs primarily in Zone 1 hepatocytes
• Regulated by carnitine palmitoyltransferase-1 (CPT-1)
• Malonyl-CoA (from carbohydrate excess) inhibits CPT-1 [60]

Ketogenesis:

• Occurs during fasting/starvation or uncontrolled diabetes
• Acetyl-CoA → acetoacetate → β-hydroxybutyrate + acetone
• Rate-limiting enzyme: HMG-CoA synthase
• Provides alternative fuel for brain and muscle
• Ketones provide 50-70% of brain energy during prolonged fasting [61]

Ammonia and Urea Cycle

Ammonia detoxification is a critical hepatic function. Failure leads to hyperammonaemia, neurotoxicity, and hepatic encephalopathy. [12,13,62]

Sources of Ammonia:

• Gut bacteria (urease activity, 50%)
• Dietary protein deamination (30%)
• Amino acid catabolism in tissues (15%)
• Purine nucleotide cycle in muscle (5%)
• Normal plasma ammonia: 10-35 μmol/L (15-50 μg/dL)

Urea Cycle (Krebs-Henseleit Cycle):

Location: Mitochondrial matrix and cytosol of Zone 1 hepatocytes

1. Carbamoyl phosphate synthetase I (CPS I) - mitochondria, rate-limiting

   • NH3 + CO2 + 2 ATP → Carbamoyl phosphate
   • Activated by N-acetylglutamate (NAG)

2. Ornithine transcarbamylase (OTC) - mitochondria

   • Carbamoyl phosphate + Ornithine → Citrulline

3. Argininosuccinate synthetase - cytosol

   • Citrulline + Aspartate + ATP → Argininosuccinate

4. Argininosuccinate lyase - cytosol

   • Argininosuccinate → Arginine + Fumarate

5. Arginase - cytosol

   • Arginine → Urea + Ornithine
   • Ornithine returns to mitochondria (ornithine-citrulline antiporter)

Urea Production:

• Normal: 20-30 g urea/day (10-15 g nitrogen)
• One nitrogen from ammonia, one from aspartate
• Requires 3 ATP per urea molecule
• High capacity system (can handle 10-fold increase in ammonia)
• Excreted by kidneys (50-70%) [63,64]

Glutamine Pathway (Zone 3):

• Alternative ammonia disposal in Zone 3 hepatocytes
• Glutamate + NH3 → Glutamine (glutamine synthetase)
• Low capacity but high affinity
• "Scavenger pathway" for residual ammonia escaping urea cycle
• Glutamine released to blood, metabolised by kidney (ammoniagenesis) and gut [65]

Ammonia in Critical Illness:

• Hyperammonaemia occurs when ammonia production exceeds hepatic clearance
• Causes: Liver failure, urea cycle defects, portosystemic shunting, GI bleeding
• Ammonia crosses blood-brain barrier, converted to glutamine in astrocytes
• Glutamine accumulation → astrocyte swelling → cerebral oedema
• Ammonia also causes oxidative stress and mitochondrial dysfunction
• Acute hyperammonaemia is more dangerous than chronic [66]

---

Drug Metabolism

Phase I Reactions

Phase I reactions introduce or expose functional groups on drug molecules, increasing their polarity and preparing them for Phase II conjugation. These reactions typically occur in hepatic microsomes (smooth endoplasmic reticulum). [14,15,67]

Cytochrome P450 (CYP450) System:

• Superfamily of haeme-containing enzymes
• Located in smooth endoplasmic reticulum (microsomes)
• Predominantly in Zone 3 hepatocytes
• Require NADPH and molecular oxygen
• Total of 57 functional human CYP genes

Major CYP450 Isoforms:

[68,69]

CYP2D6 Polymorphisms:

• Highly polymorphic gene (>100 alleles described)
• Poor metabolisers (PM, 7% Caucasians): No functional enzyme
  • Codeine → no analgesia (prodrug not converted to morphine)
  • Tramadol → reduced effect
  • SSRIs → toxicity
• Extensive metabolisers (EM): Normal activity
• Ultra-rapid metabolisers (UM, 1-3%): Gene duplication
  • Codeine → rapid conversion to morphine → toxicity, respiratory depression
  • Deaths reported, especially in breastfed infants
• Important for individualised drug therapy [70]

Other Phase I Reactions:

Oxidation (non-CYP450):

• Monoamine oxidases (MAO-A, MAO-B): Catecholamines, serotonin
• Alcohol dehydrogenase: Ethanol → acetaldehyde
• Aldehyde dehydrogenase: Acetaldehyde → acetate
• Xanthine oxidase: Purines

Reduction:

• Ketone reduction (warfarin)
• Nitro reduction (nitrazepam)
• Azo reduction

Hydrolysis:

• Esterases: Suxamethonium, remifentanil, esmolol
• Amidases: Lidocaine
• Peptidases [71]

Phase II Reactions

Phase II reactions conjugate Phase I products (or drugs with existing functional groups) with endogenous molecules, producing highly polar, water-soluble metabolites for renal or biliary excretion. [72,73]

Glucuronidation:

• Most common conjugation reaction
• UDP-glucuronosyltransferases (UGTs)
• Conjugates with glucuronic acid
• Substrates: Morphine (morphine-6-glucuronide active), paracetamol, bilirubin
• UGT1A1: Bilirubin conjugation (Gilbert syndrome = UGT1A1 polymorphism)
• Products excreted in bile and urine

Sulfation:

• Sulfotransferases (SULTs)
• Conjugates with sulfate (from PAPS)
• Lower capacity than glucuronidation
• Substrates: Paracetamol, steroids, catecholamines

Acetylation:

• N-acetyltransferases (NAT1, NAT2)
• NAT2 polymorphism: Slow vs fast acetylators
• Slow acetylators (50% Caucasians, 10% Asians): Increased risk of isoniazid toxicity
• Substrates: Isoniazid, hydralazine, procainamide, sulfonamides

Glutathione Conjugation:

• Glutathione-S-transferases (GSTs)
• Critical for detoxification of reactive intermediates
• Paracetamol toxicity: NAPQI depletes glutathione → hepatotoxicity
• N-acetylcysteine replenishes glutathione stores

Methylation:

• Methyltransferases (COMT, TPMT, TMPT)
• COMT: Catecholamine metabolism
• TPMT polymorphism: Azathioprine/6-mercaptopurine toxicity in poor metabolisers

Amino Acid Conjugation:

• Glycine, taurine conjugation
• Bile acid conjugation with glycine (glycocholic acid) or taurine (taurocholic acid)

First-Pass Effect

The first-pass effect (presystemic metabolism) describes the loss of drug during the first passage through the gut wall and liver after oral administration. [74,75]

Components:

1. Intestinal metabolism: CYP3A4 and UGTs in enterocytes
2. Hepatic metabolism: Portal blood delivers drug directly to hepatocytes

Consequences:

• Reduced oral bioavailability (F)
• F = fraction absorbed × (1 - intestinal extraction) × (1 - hepatic extraction)
• High first-pass drugs: Morphine (F ~25%), propranolol (F ~25%), GTN (F ~2%), lidocaine (F ~35%)
• Bypassed by: IV, sublingual, transdermal, rectal (partially) routes

In Liver Disease:

• Reduced first-pass effect due to:
  • Portosystemic shunting
  • Reduced hepatocyte mass
  • Reduced enzyme activity
• Oral bioavailability increases
• Dose reduction required for high first-pass drugs [76]

Hepatic Extraction Ratio and Clearance

Understanding hepatic clearance is essential for drug dosing in liver disease. The extraction ratio determines how blood flow and enzyme activity affect drug clearance. [16,17,77]

Hepatic Clearance Equation:

CLH = Q × ER = Q × (fu × CLint) / (Q + fu × CLint)

Where:

• CLH = hepatic clearance (mL/min)
• Q = hepatic blood flow (~1500 mL/min)
• ER = extraction ratio (0-1)
• fu = unbound (free) fraction
• CLint = intrinsic clearance (enzyme capacity)

High Extraction Ratio Drugs (ER >0.7):

• Clearance is flow-dependent
• CLH ≈ Q (limited by blood flow, not enzyme capacity)
• Examples: Morphine, propranolol, lidocaine, verapamil, labetalol, GTN
• In liver disease: Flow reduction reduces clearance
• Dosing adjustment: Reduce dose if portal flow decreased (portal hypertension, shock)

Low Extraction Ratio Drugs (ER <0.3):

• Clearance is capacity-dependent (enzyme-limited)
• CLH ≈ fu × CLint
• Examples: Diazepam, warfarin, phenytoin, theophylline
• In liver disease: Enzyme reduction reduces clearance
• Dosing adjustment: Reduce dose based on synthetic function (albumin, INR)

Intermediate Extraction Ratio (ER 0.3-0.7):

• Clearance depends on both flow and enzyme capacity
• Examples: Midazolam, codeine, aspirin

Protein Binding Effects:

• Albumin binds acidic drugs (warfarin, phenytoin, NSAIDs)
• α1-acid glycoprotein binds basic drugs (lidocaine, propranolol, fentanyl)
• Hypoalbuminaemia increases free fraction:
  • "For high ER drugs: No effect on total clearance (bound and free drug equally cleared)"
  • "For low ER drugs: Increased clearance of total drug, steady-state concentration unchanged"
• Clinical effect depends on therapeutic window and distribution [78,79]

---

Bile Production and Secretion

Bile Composition

Bile is a complex fluid essential for lipid digestion and excretion of cholesterol, bilirubin, and xenobiotics. The liver produces 500-1000 mL/day of hepatic bile. [18,19,80]

Composition of Hepatic Bile:

• Water: 95%
• Bile acids (salts): 0.7% (12-18 mmol/L)
• Phospholipids: 0.5% (4-8 mmol/L)
• Cholesterol: 0.3% (3-5 mmol/L)
• Bilirubin: 0.05% (1-2 mmol/L)
• Proteins, electrolytes, bicarbonate

Bile Acids:

Primary Bile Acids (synthesised from cholesterol):

• Cholic acid (3α,7α,12α-trihydroxy)
• Chenodeoxycholic acid (CDCA) (3α,7α-dihydroxy)
• Synthesis: CYP7A1 (rate-limiting), CYP8B1, CYP27A1
• Daily synthesis: 500-600 mg (15-20 μmol/kg/day)

Secondary Bile Acids (bacterial modification in gut):

• Deoxycholic acid (from cholic acid)
• Lithocholic acid (from CDCA)

Conjugated Bile Acids:

• Glycine conjugates (75%): Glycocholic, glycochenodeoxycholic
• Taurine conjugates (25%): Taurocholic, taurochenodeoxycholic
• Conjugation lowers pKa, preventing passive reabsorption in proximal gut
• Allows active reabsorption in terminal ileum [81]

Bile Acid Enterohepatic Circulation

The enterohepatic circulation recycles 95% of bile acids, maintaining the bile acid pool with minimal new synthesis. [82,83]

Cycle Steps:

1. Bile acids secreted into bile (BSEP transporter)
2. Stored in gallbladder (concentrated 5-10 fold)
3. Released into duodenum post-prandially (CCK-mediated)
4. Emulsify dietary lipids, form mixed micelles
5. Most remain in gut lumen (not absorbed with micelles)
6. Active reabsorption in terminal ileum (ASBT transporter)
7. Portal venous return to liver
8. Hepatocyte uptake (NTCP transporter)
9. Re-secretion into bile

Quantitative Aspects:

• Bile acid pool: 2-4 g
• Pool cycles 6-12 times/day
• Daily secretion: 12-36 g bile acids
• Faecal loss: 5% daily (500-600 mg)
• New synthesis matches faecal loss

Regulation:

• FXR (farnesoid X receptor): Bile acid sensor
• High bile acids → FXR activation → ↓ CYP7A1 → ↓ synthesis
• FXR agonists: Obeticholic acid (used in cholestatic liver disease)

Canalicular Transport

Major Transporters:

[84,85]

Bile Flow Types:

• Bile acid-dependent flow: 40-50% (driven by osmotic effect of bile acids)
• Bile acid-independent flow: 50-60% (driven by bicarbonate secretion via AE2 and glutathione)

---

Bilirubin Metabolism

Bilirubin Production

Bilirubin is the end product of haeme catabolism, predominantly from senescent red blood cells. Understanding its metabolism is essential for interpreting jaundice. [86,87]

Sources of Bilirubin:

• Haemoglobin from senescent RBCs (80-85%)
• Hepatic haeme (CYP450, catalase): 10-15%
• Ineffective erythropoiesis: 3-5%
• Myoglobin: <1%

Daily Production:

• 250-400 mg bilirubin/day
• 4 mg/kg/day

Haeme Degradation Pathway:

1. Haeme → Biliverdin (haeme oxygenase, rate-limiting)
   • Releases CO and Fe2+
2. Biliverdin → Bilirubin (biliverdin reductase)
   • Produces unconjugated (indirect) bilirubin

Unconjugated vs Conjugated Bilirubin

Unconjugated (Indirect) Bilirubin:

• Lipophilic, water-insoluble
• Tightly bound to albumin (Kb = 10^8 M^-1)
• Cannot be filtered by kidneys (not in urine)
• Neurotoxic when unbound (kernicterus in neonates)
• Normal: 5-12 μmol/L

Conjugated (Direct) Bilirubin:

• Hydrophilic, water-soluble
• Glucuronide conjugates (mono- and di-glucuronide)
• Loosely albumin-bound
• Can be filtered by kidneys (appears in urine → dark urine)
• Not neurotoxic
• Normal: <5 μmol/L (usually undetectable) [88]

Hepatic Handling of Bilirubin

Step 1: Hepatocyte Uptake

• Sinusoidal membrane transporters: OATP1B1, OATP1B3
• Bilirubin dissociates from albumin
• Cytoplasmic binding proteins (ligandin/GST) prevent efflux

Step 2: Conjugation

• UGT1A1 (UDP-glucuronosyltransferase 1A1)
• Location: Smooth endoplasmic reticulum
• Bilirubin → Bilirubin monoglucuronide → Bilirubin diglucuronide
• Makes bilirubin water-soluble for excretion

Step 3: Canalicular Secretion

• MRP2 (ABCC2) transporter
• Rate-limiting step in bilirubin excretion
• Secretes conjugated bilirubin into bile [89]

Intestinal Fate and Enterohepatic Circulation

In the Gut:

1. Conjugated bilirubin not absorbed in small intestine
2. Reaches colon, deconjugated by bacterial β-glucuronidase
3. Reduced by bacteria to urobilinogens (colourless)
4. Urobilinogens oxidised to urobilin (brown) and stercobilin → faecal colour

Enterohepatic Circulation:

• 20% of urobilinogen reabsorbed from colon
• Returns to liver via portal vein
• Re-excreted in bile (80%)
• Small amount excreted by kidneys (urinary urobilinogen)

Clinical Notes:

• Absent faecal urobilinogen → pale stools (biliary obstruction)
• Absent urinary urobilinogen → complete biliary obstruction
• Increased urinary urobilinogen → haemolysis, hepatocellular disease [90]

Classification of Jaundice

Conjugated Hyperbilirubinaemia Syndromes:

• Dubin-Johnson syndrome: MRP2 deficiency
• Rotor syndrome: OATP1B1/1B3 deficiency

Unconjugated Hyperbilirubinaemia Syndromes:

• Gilbert syndrome: UGT1A1 polymorphism (6% population), benign, mild ↑ with fasting/stress
• Crigler-Najjar Type I: Complete UGT1A1 deficiency, severe, fatal without transplant
• Crigler-Najjar Type II: Partial UGT1A1 deficiency, responds to phenobarbital [91,92]

---

Synthetic Function Assessment

Albumin

Clinical Significance:

• Half-life: 20 days → reflects chronic (not acute) synthetic function
• <28 g/L: Clinically significant hypoalbuminaemia
• Falls in chronic liver disease, nephrotic syndrome, protein-losing enteropathy, malnutrition
• Negative acute phase reactant (falls in inflammation independent of liver function)
• Prognostic marker (component of Child-Pugh, MELD-Plus) [51,52]

Limitations:

• Slow response to acute liver injury (unsuitable for acute liver failure)
• Confounded by inflammation (sepsis, surgery)
• Haemodilution in fluid resuscitation
• Capillary leak in critical illness

Prothrombin Time/INR

Basis:

• Measures extrinsic pathway: Factors VII, X, V, II, I (fibrinogen)
• Factor VII has shortest half-life (4-6 hours)
• Sensitive early marker of acute hepatic synthetic dysfunction

Interpretation in Liver Disease:

• Prolongation occurs when factors fall <30% of normal
• INR >1.5 indicates significant synthetic impairment
• Used in King's College Criteria (paracetamol ALF: INR >3.0 at 48h, >4.5 at 72h)
• Used in MELD score calculation [53,54]

Limitations:

• Affected by vitamin K deficiency (malabsorption, malnutrition, antibiotics)
• Affected by warfarin therapy
• May not reflect bleeding risk (balanced haemostasis in cirrhosis)
• Does not account for decreased anticoagulant factors (Protein C, S, AT)

Factor V Level

Unique Characteristics:

• Not vitamin K dependent (unlike II, VII, IX, X)
• Short half-life (12-36 hours)
• Pure synthetic function marker
• Not affected by vitamin K, not replaced by FFP in DIC

Clinical Use:

• Factor V <20%: Poor prognosis in acute liver failure (Clichy criteria)
• Distinguishes synthetic failure from vitamin K deficiency
• Vitamin K administration does not improve Factor V
• Factor V >50%: Good prognostic indicator for spontaneous recovery [93]

Other Markers

Prealbumin (Transthyretin):

• Half-life: 2 days
• More sensitive to acute changes than albumin
• Reflects nutritional status and short-term synthetic function
• Negative acute phase reactant

Clotting Factor Activity:

• Factor VIII: Elevated in liver disease (synthesised by endothelium, not liver)
• Factor VII: Earliest to fall, shortest half-life
• Fibrinogen: May be low (synthetic failure) or elevated (acute phase)

---

Hepatic Encephalopathy

Pathophysiology

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome occurring in liver failure or portosystemic shunting. It represents a spectrum from minimal HE to coma. [12,13,94,95]

Ammonia Hypothesis:

Ammonia Sources:

• Gut: Bacterial urease, protein catabolism
• Kidneys: Glutaminase activity
• Muscle: Protein catabolism (deamination)

Ammonia in Brain:

1. Ammonia crosses blood-brain barrier
2. Astrocytes take up ammonia (neurons cannot)
3. Glutamine synthetase: Glutamate + NH3 → Glutamine
4. Glutamine accumulates intracellularly (osmolyte)
5. Astrocyte swelling → cerebral oedema
6. Impaired astrocyte function → altered neurotransmission

Low-Grade Cerebral Oedema:

• Chronic HE: Compensatory osmolyte extrusion (myo-inositol, taurine)
• Acute HE: Insufficient time for compensation → overt cerebral oedema
• MRI shows increased T2 signal in globus pallidus (manganese deposition)
• Astrocyte morphology: Alzheimer type II astrocytosis [96,97]

GABA/Benzodiazepine Hypothesis:

• Increased GABA-ergic tone in HE
• Endogenous benzodiazepine-like compounds identified
• Increased brain benzodiazepine receptor binding
• Explains improvement with flumazenil in some patients [98]

Other Factors:

• Inflammation and infection: Precipitate HE in cirrhosis
• Hyponatraemia: Compounds astrocyte swelling
• Systemic inflammatory response: Cytokines exacerbate neurotoxicity
• Manganese accumulation: Basal ganglia deposition
• Reduced zinc: Impaired urea cycle function [99]

Clinical Grading

West Haven Criteria:

Precipitants in Cirrhosis:

• GI bleeding (protein load, hypovolaemia)
• Infection/sepsis (50% have occult infection)
• Constipation (increased ammonia production)
• Electrolyte disturbance (hypokalaemia, hyponatraemia)
• Drugs (sedatives, diuretics, opioids)
• TIPS procedure
• Dehydration
• Dietary protein excess [100]

Management Principles

General Measures:

• Identify and treat precipitants (infection, GI bleeding)
• Avoid sedatives (especially benzodiazepines)
• Airway protection if Grade III-IV
• Nutritional support (protein 1.2-1.5 g/kg/day, not restriction)
• Correct electrolyte disturbances

Specific Therapies:

Lactulose:

• Non-absorbable disaccharide
• Acidifies colon → traps ammonia as NH4+
• Cathartic effect → reduces transit time
• Alters gut flora
• Target: 2-3 soft bowel movements/day
• Evidence: Modest quality, widely used [101]

Rifaximin:

• Non-absorbed antibiotic
• Reduces ammonia-producing bacteria
• 550 mg twice daily
• Used with lactulose for secondary prophylaxis
• Rifaximin + lactulose superior to lactulose alone (NEJM 2010) [102]

Other:

• L-ornithine L-aspartate (LOLA): Ammonia metabolism enhancement
• Zinc supplementation: Supports urea cycle enzymes
• Polyethylene glycol: More effective than lactulose for acute HE in some studies [103]

---

Acute Liver Failure Physiology

Definition and Classification

Definition:

• Acute liver failure: Severe acute liver injury with coagulopathy (INR ≥1.5) and any degree of encephalopathy in a patient without pre-existing liver disease

Classification by Onset:

• Hyperacute: <7 days (paracetamol, hepatitis A/B) → better prognosis, higher cerebral oedema risk
• Acute: 7-21 days
• Subacute: 21-26 weeks → worse prognosis, lower cerebral oedema risk [104,105]

Multi-Organ Dysfunction

Coagulopathy:

• Reduced synthesis of all clotting factors (except VIII)
• Reduced anticoagulant factors (Protein C, S, Antithrombin)
• "Balanced haemostasis"
• may be hypercoagulable despite elevated INR
• Thromboelastography (TEG/ROTEM) better reflects haemostatic status
• Bleeding risk: Mucosal, GI, intracranial
• Thrombosis risk: Portal vein thrombosis, DVT [106]

Cerebral Oedema:

• Occurs in 50-80% of Grade IV HE
• Leading cause of death in hyperacute ALF
• Pathophysiology: Astrocyte swelling (glutamine), loss of autoregulation, hyperaemia
• Signs: Pupillary changes, posturing, Cushing response
• Management: Avoid hyperventilation, maintain CPP, mannitol, hypertonic saline
• ICP monitoring controversial (bleeding risk) [107,108]

Cardiovascular:

• Hyperdynamic circulation (high CO, low SVR)
• Similar to septic shock physiology
• Myocardial depression (cytokines)
• Relative adrenal insufficiency
• High lactate (impaired clearance and increased production) [109]

Respiratory:

• ARDS in severe cases
• Aspiration risk with encephalopathy
• Hepatopulmonary syndrome (V/Q mismatch, shunting)
• Pulmonary oedema (fluid resuscitation)

Renal:

• AKI in 50-70% of patients
• Hepatorenal syndrome (functional renal failure)
• Direct nephrotoxicity (paracetamol)
• Prerenal azotaemia (bleeding, poor intake)
• Continuous renal replacement therapy (CRRT) for metabolic control

Metabolic:

• Hypoglycaemia: Impaired gluconeogenesis, glycogen depletion
  • Requires glucose infusion (D10W or D50W boluses)
  • Refractory hypoglycaemia predicts poor outcome
• Lactic acidosis: Impaired lactate clearance, tissue hypoperfusion
• Hypophosphataemia: Phosphorus consumption in regenerating hepatocytes
• Hyponatraemia: Impaired free water excretion [110]

Infection:

• Impaired immune function (reduced complement, Kupffer cell dysfunction)
• Bacterial infection: 80% develop infection (pneumonia, UTI, line sepsis)
• Fungal infection: 30% (especially Candida, Aspergillus)
• Prophylactic antibiotics controversial but often used
• Low threshold for empirical broad-spectrum antibiotics [111]

Prognostic Scoring

King's College Criteria (Paracetamol-Induced ALF):

Transplant if:

• Arterial pH <7.3 after resuscitation

OR all three of:

• INR >6.5 (PT >100 sec)
• Creatinine >300 μmol/L
• Grade III-IV encephalopathy

King's College Criteria (Non-Paracetamol ALF):

Transplant if:

• INR >6.5 (PT >100 sec)

OR any three of:

• Age <10 or >40 years
• Aetiology: Non-A, non-B hepatitis, drug-induced
• Duration of jaundice before encephalopathy >7 days
• INR >3.5 (PT >50 sec)
• Bilirubin >300 μmol/L

[112]

MELD Score:

MELD = 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43

• Validated for prioritising liver transplant allocation
• Higher score = higher 90-day mortality without transplant
• MELD >30: High mortality
• Does not include encephalopathy (unlike Child-Pugh) [113,114]

---

Portal Hypertension

Pathophysiology

Portal hypertension is defined as hepatic venous pressure gradient (HVPG) ≥6 mmHg. Clinically significant portal hypertension (CSPH) is HVPG ≥10 mmHg. [22,115]

Normal Portal Physiology:

• Portal vein pressure: 5-10 mmHg
• Hepatic venous pressure: 0-5 mmHg
• HVPG = Wedged hepatic venous pressure - Free hepatic venous pressure = 1-5 mmHg

Causes of Portal Hypertension:

Prehepatic (portal vein obstruction):

• Portal vein thrombosis
• Splenic vein thrombosis
• Extrinsic compression

Intrahepatic (most common):

• Cirrhosis (90% of cases)
• Schistosomiasis (presinusoidal)
• Nodular regenerative hyperplasia
• Veno-occlusive disease (sinusoidal obstruction syndrome)

Posthepatic:

• Budd-Chiari syndrome
• Right heart failure
• Constrictive pericarditis
• IVC obstruction

Mechanisms in Cirrhosis:

1. Increased intrahepatic resistance:

   • Structural: Fibrosis, nodular regeneration, capillarisation of sinusoids
   • Dynamic: Stellate cell contraction (ET-1, reduced NO)
   • Dynamic component contributes 20-30% of resistance

2. Increased splanchnic blood flow:

   • Splanchnic vasodilation (NO-mediated)
   • Hyperdynamic circulation
   • Angiogenesis
   • Perpetuates portal hypertension [116,117]

Consequences of Portal Hypertension

Varices:

• Develop at HVPG ≥10 mmHg
• Bleed at HVPG ≥12 mmHg
• Sites: Gastroesophageal (most common), anorectal, stomal
• Mortality per variceal bleed: 15-20%
• Primary prophylaxis: Non-selective beta-blockers (carvedilol, propranolol), endoscopic band ligation

Ascites:

• Develops at HVPG ≥10-12 mmHg
• Pathophysiology:
  1. Sinusoidal hypertension → increased hepatic lymph production
  2. Splanchnic vasodilation → arterial underfilling
  3. Activation of RAAS, SNS, ADH → sodium and water retention
  4. Capillary leak → ascites formation
• Management: Sodium restriction, diuretics (spironolactone + furosemide), paracentesis, TIPS

Hepatorenal Syndrome:

• Functional renal failure in advanced cirrhosis
• Type 1: Rapid deterioration (creatinine doubles in <2 weeks)
• Type 2: Gradual deterioration (refractory ascites)
• Pathophysiology: Splanchnic vasodilation → reduced effective circulating volume → intense renal vasoconstriction
• Diagnosis of exclusion (no structural renal disease)
• Treatment: Terlipressin + albumin, liver transplantation [118]

Hepatopulmonary Syndrome:

• Triad: Liver disease, intrapulmonary vascular dilatation, hypoxaemia
• Shunting and V/Q mismatch
• Platypnoea-orthodeoxia (hypoxia worsens upright)
• Diagnosis: Contrast echocardiography (bubble study)
• Treatment: Liver transplantation

Portopulmonary Hypertension:

• Pulmonary artery hypertension with portal hypertension
• mPAP ≥25 mmHg, PVR >240 dynes.s.cm-5, PCWP <15 mmHg
• Complicates 5-10% of liver transplant candidates
• May preclude transplantation if severe [119]

---

Clinical Applications

Drug Dosing in Liver Failure

Principles:

1. Assess severity: Child-Pugh score, MELD score
2. Determine extraction ratio of drug
3. Consider protein binding changes
4. Adjust loading doses for volume of distribution changes
5. Adjust maintenance doses for clearance changes
6. Monitor drug levels where possible [76,120]

Drug Classes:

Child-Pugh Classification:

• Class A: 5-6 points (1-year survival 100%)
• Class B: 7-9 points (1-year survival 81%)
• Class C: 10-15 points (1-year survival 45%)

MELD Score and Transplant Allocation

MELD Formula:

MELD = 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43

• Minimum values set to 1.0 for ln calculations
• Maximum creatinine capped at 4.0 mg/dL (353 μmol/L)
• Dialysis patients: Creatinine set at 4.0 mg/dL
• Range: 6-40 (recalculated as MELD 3.0 with sodium included)

3-Month Mortality by MELD:

• MELD <10: 2% mortality
• MELD 10-19: 6% mortality
• MELD 20-29: 20% mortality
• MELD 30-39: 50% mortality
• MELD ≥40: 70% mortality

MELD-Na:

• Incorporates serum sodium for improved prediction
• MELD-Na = MELD + 1.32 × (137 - Na) - 0.033 × MELD × (137 - Na)
• Used for transplant allocation in many jurisdictions [113,114]

Australian/New Zealand Context

Indigenous Health Considerations:

Aboriginal and Torres Strait Islander Populations:

• Higher rates of hepatitis B (4-fold higher prevalence)
• Higher rates of hepatitis C (injection drug use, incarceration)
• Higher rates of alcohol-related liver disease
• Barriers to care: Geography, cultural factors, healthcare access
• Cultural competence: Involvement of Aboriginal Health Workers
• Family involvement in decision-making
• Consideration of return to Country for end-of-life care

Māori Health Considerations:

• Higher rates of hepatitis B (particularly in older adults)
• Whānau-centred care models
• Tikanga protocols (cultural practices)
• Engagement with kaumātua (elders) for major decisions
• Te Tiriti o Waitangi obligations [121,122]

Liver Transplant Services:

• Australian National Liver Transplant Unit (ANLTU) allocation
• Centres: Austin Hospital (Melbourne), Royal Prince Alfred (Sydney), Princess Alexandra (Brisbane), Flinders (Adelaide), Sir Charles Gairdner (Perth)
• New Zealand: Auckland City Hospital
• Living donor liver transplant programs available
• MELD-based allocation with exception points
• Mean wait time: Variable by blood group and MELD score [123]

ANZICS Acute Liver Failure Registry:

• Prospective database of ALF outcomes
• Australian aetiology differs from UK/US (more non-A-E hepatitis, less paracetamol)
• Indigenous patients underrepresented in transplant outcomes
• Regional variation in access to transplant services [124]

---

SAQ Practice

SAQ 1: Hepatic Blood Supply and Drug Metabolism (15 marks)

Question: A 45-year-old man with alcoholic cirrhosis (Child-Pugh C) requires analgesia. His serum albumin is 22 g/L and INR is 2.8.

(a) Describe the dual blood supply to the liver and the hepatic artery buffer response. (5 marks)

(b) Explain the phases of hepatic drug metabolism and how cirrhosis affects each phase. (5 marks)

(c) Discuss the pharmacokinetic changes affecting morphine and propranolol dosing in this patient. (5 marks)

---

Model Answer:

(a) Dual Blood Supply and HABR (5 marks)

Dual Blood Supply (3 marks):

• Portal vein: 75% of blood flow (1000-1200 mL/min), 50% O2 delivery, low pressure (7-10 mmHg), low O2 saturation (85%)
• Hepatic artery: 25% of blood flow (300-400 mL/min), 50% O2 delivery, high pressure (MAP), high O2 saturation (95-100%)
• Total hepatic blood flow: 1500 mL/min (25% cardiac output)
• Unique dual supply allows tolerance of single-vessel occlusion

Hepatic Artery Buffer Response (2 marks):

• Adenosine-mediated semi-reciprocal regulation
• When portal flow decreases, adenosine accumulates (normally washed out by portal blood)
• Adenosine acts on A2 receptors → hepatic artery vasodilation → increased hepatic arterial flow
• Compensates 25-60% of portal flow reduction
• Maintains hepatic oxygen delivery
• Impaired in cirrhosis due to architectural distortion and endothelial dysfunction

(b) Phases of Drug Metabolism and Cirrhosis Effects (5 marks)

Phase I Reactions (2.5 marks):

• Oxidation, reduction, hydrolysis
• Primarily CYP450 enzymes in smooth endoplasmic reticulum
• Zone 3 hepatocytes predominate
• In cirrhosis:
  • Reduced hepatocyte mass → reduced enzyme content
  • Portosystemic shunting → bypasses first-pass metabolism
  • Hypoxia of Zone 3 → impaired CYP450 activity
  • CYP3A4, CYP1A2 most affected; CYP2D6 relatively preserved

Phase II Reactions (2.5 marks):

• Conjugation: Glucuronidation, sulfation, acetylation, glutathione conjugation
• Produce water-soluble metabolites for excretion
• In cirrhosis:
  • Glucuronidation relatively preserved until advanced disease
  • Sulfation capacity limited (low substrate availability)
  • Acetylation preserved (extrahepatic metabolism significant)
  • "Overall: Phase II less affected than Phase I"

(c) Pharmacokinetic Changes - Morphine and Propranolol (5 marks)

Morphine (High Extraction Ratio Drug) (2.5 marks):

• Hepatic extraction ratio: 0.7-0.8
• First-pass effect normally reduces oral bioavailability to 25%
• In cirrhosis:
  • Reduced first-pass → increased oral bioavailability (may double)
  • Portosystemic shunting → bypasses hepatic metabolism
  • Glucuronidation relatively preserved initially
  • But morphine-6-glucuronide (active) accumulates with renal dysfunction
  • "Clinical effect: Increased sensitivity, prolonged duration"
  • "Dosing: Reduce dose by 50%, increase dosing interval"

Propranolol (High Extraction Ratio Drug) (2.5 marks):

• Hepatic extraction ratio: 0.7-0.9
• Oral bioavailability normally 25-35%
• In cirrhosis:
  • Reduced first-pass → oral bioavailability increases to 50-60%
  • Flow-dependent clearance reduced by decreased portal flow
  • Alpha-1-acid glycoprotein often increased in cirrhosis → increased binding
  • However, free fraction may be increased due to hypoalbuminaemia for other drugs
  • Volume of distribution may be increased (ascites)
  • "Clinical effect: Increased plasma levels, prolonged half-life"
  • "Dosing: Start low (20 mg once daily), titrate slowly"

---

SAQ 2: Bilirubin Metabolism and Hepatic Encephalopathy (15 marks)

Question: A 58-year-old woman with chronic hepatitis C cirrhosis presents with confusion, asterixis, and jaundice. Her ammonia is 180 μmol/L (normal <50) and bilirubin is 220 μmol/L (conjugated 180 μmol/L).

(a) Describe the pathway of bilirubin metabolism from production to excretion. (5 marks)

(b) Explain the pattern of hyperbilirubinaemia in this patient and differentiate from haemolytic jaundice. (4 marks)

(c) Describe the pathophysiology of hepatic encephalopathy and the role of ammonia. (6 marks)

---

Model Answer:

(a) Bilirubin Metabolism Pathway (5 marks)

Production (1 mark):

• Senescent RBC breakdown in reticuloendothelial system (spleen, liver)
• Haeme → Biliverdin (haeme oxygenase) → Unconjugated bilirubin (biliverdin reductase)
• Daily production: 250-400 mg (4 mg/kg/day)
• 80-85% from haemoglobin, 15-20% from hepatic haeme and ineffective erythropoiesis

Transport (1 mark):

• Unconjugated bilirubin: Lipophilic, water-insoluble
• Tightly bound to albumin for transport in blood
• Cannot be filtered by kidneys (not in urine)

Hepatic Uptake and Conjugation (1.5 marks):

• Hepatocyte uptake via OATP1B1/1B3 transporters
• Bound to ligandin (GST) in cytoplasm
• Conjugation with glucuronic acid by UGT1A1 in smooth ER
• Forms bilirubin monoglucuronide and diglucuronide
• Conjugated bilirubin: Water-soluble

Excretion (1.5 marks):

• Canalicular secretion via MRP2 transporter (rate-limiting)
• Enters bile → stored in gallbladder → released into duodenum
• In colon: Deconjugated by bacterial β-glucuronidase → reduced to urobilinogen
• Urobilinogen oxidised to urobilin/stercobilin (faecal pigment)
• 20% urobilinogen reabsorbed → enterohepatic circulation

(b) Pattern of Hyperbilirubinaemia (4 marks)

This Patient - Hepatocellular/Cholestatic Pattern (2 marks):

• Predominantly conjugated hyperbilirubinaemia (180/220 = 82% conjugated)
• Indicates hepatocellular dysfunction and/or intrahepatic cholestasis
• Mechanisms:
  • Reduced canalicular excretion (MRP2 dysfunction)
  • Reflux of conjugated bilirubin back into blood
  • Hepatocyte necrosis releasing intracellular conjugated bilirubin
• Urine: Dark (conjugated bilirubin excreted by kidneys)
• Stool: May be pale (reduced bile reaching gut)

Differentiation from Haemolytic Jaundice (2 marks):

(c) Pathophysiology of Hepatic Encephalopathy (6 marks)

Ammonia Sources and Clearance (2 marks):

• Sources: Gut bacteria (urease, 50%), dietary protein deamination, tissue amino acid catabolism
• Normal clearance: Urea cycle in Zone 1 hepatocytes (85%), glutamine synthesis in Zone 3 (15%)
• In cirrhosis: Reduced urea cycle capacity (loss of hepatocyte mass), portosystemic shunting bypasses liver
• This patient: Ammonia 180 μmol/L (3.6× normal) indicates severe impairment

Brain Ammonia Metabolism (2 marks):

• Ammonia freely crosses blood-brain barrier
• Neurons lack ammonia detoxification capacity
• Astrocytes contain glutamine synthetase: Glutamate + NH3 → Glutamine
• Glutamine accumulates → acts as osmolyte → astrocyte swelling
• Chronic: Compensatory osmolyte (myo-inositol, taurine) extrusion
• Acute: Insufficient compensation → cerebral oedema

Neurotoxicity Mechanisms (2 marks):

• Astrocyte swelling → altered neurotransmitter release and uptake
• Impaired glutamatergic and GABAergic neurotransmission
• Increased intracellular glutamine → mitochondrial dysfunction → oxidative stress
• Manganese accumulation in basal ganglia (normally excreted in bile)
• Increased GABA-ergic tone and endogenous benzodiazepine-like compounds
• Inflammation synergy: Systemic inflammation potentiates ammonia neurotoxicity
• Blood-brain barrier dysfunction: Increased permeability to toxins

---

Viva Scenarios

Viva Scenario 1: Hepatic Blood Flow and Drug Clearance

Setting: First Part Physiology Viva. You are shown a diagram of the hepatic circulation and asked to discuss hepatic blood flow and drug metabolism.

---

Examiner: Please describe the blood supply to the liver.

Candidate: The liver has a unique dual blood supply receiving approximately 25% of cardiac output, which is about 1500 mL/min in a 70 kg adult.

The portal vein provides 75% of hepatic blood flow—around 1000-1200 mL/min. It carries blood from the splanchnic circulation, so it's nutrient-rich but has low oxygen content, with an oxygen saturation of about 85% and a PO2 of approximately 40 mmHg. Despite providing 75% of the blood flow, the portal vein delivers only about 50% of the liver's oxygen supply due to its lower oxygen content. It's a low-pressure system, typically 7-10 mmHg, and has no valves.

The hepatic artery provides 25% of hepatic blood flow—around 300-400 mL/min. It's a branch of the coeliac axis and carries fully oxygenated blood with an oxygen saturation of 95-100% and PO2 around 100 mmHg. Despite providing only 25% of blood flow, it delivers 50% of hepatic oxygen. It's a high-pressure system and can autoregulate over a range of mean arterial pressures from 60 to 140 mmHg.

Blood from both vessels mixes in the hepatic sinusoids and drains via the three hepatic veins into the inferior vena cava.

---

Examiner: What is the hepatic artery buffer response?

Candidate: The hepatic artery buffer response, or HABR, is a semi-reciprocal mechanism whereby hepatic arterial blood flow increases when portal venous flow decreases.

The mechanism is adenosine-mediated. Adenosine is continuously produced by hepatocytes and normally washed away by portal blood flow. When portal flow decreases, adenosine accumulates in the space of Mall—the periportal connective tissue space. This adenosine acts on A2 receptors on hepatic artery smooth muscle cells, causing vasodilation and increased hepatic arterial flow.

The compensation is incomplete, typically restoring only 25-60% of the decrease in portal flow. Importantly, it's unidirectional—the hepatic artery doesn't decrease when portal flow increases.

This mechanism is clinically relevant because it helps maintain hepatic oxygen delivery when portal flow is reduced, such as during splanchnic vasoconstriction in shock. However, it's impaired in cirrhosis due to architectural distortion and endothelial dysfunction. It can also be inhibited by adenosine receptor antagonists like aminophylline.

---

Examiner: How does the hepatic extraction ratio affect drug clearance?

Candidate: The hepatic extraction ratio is the fraction of drug removed from blood during a single passage through the liver, ranging from 0 to 1. It fundamentally determines how a drug's clearance responds to changes in hepatic blood flow versus intrinsic hepatic metabolic capacity.

The relationship is described by the equation: Hepatic clearance equals hepatic blood flow multiplied by extraction ratio, which also equals (fu × CLint) divided by (Q + fu × CLint), where fu is the unbound fraction and CLint is the intrinsic clearance.

High extraction ratio drugs—those with ER greater than 0.7—have flow-dependent clearance. Their clearance approximates hepatic blood flow because the liver's metabolic capacity far exceeds what blood flow delivers. Examples include morphine, propranolol, lidocaine, and verapamil. In liver disease, if portal flow is reduced due to shunting, clearance falls. Their oral bioavailability is normally low due to extensive first-pass metabolism, but increases dramatically when first-pass is impaired.

Low extraction ratio drugs—those with ER less than 0.3—have capacity-dependent clearance. Their clearance equals the unbound fraction times intrinsic clearance. Blood flow changes don't significantly affect their clearance because only a small proportion is metabolised per pass. Examples include warfarin, diazepam, phenytoin, and theophylline. In liver disease, reduced enzyme capacity reduces clearance. Their oral bioavailability is high because first-pass metabolism is minimal.

---

Examiner: How would you adjust morphine dosing in a patient with cirrhosis?

Candidate: Morphine is a high extraction ratio drug with an ER of 0.7-0.8 and normally low oral bioavailability of about 25% due to extensive first-pass metabolism. In cirrhosis, several pharmacokinetic changes occur that necessitate dose adjustment.

First, reduced first-pass metabolism due to portosystemic shunting and reduced hepatic blood flow means oral bioavailability may double or triple. A standard oral dose would produce much higher plasma concentrations.

Second, reduced hepatic clearance occurs because morphine's clearance is flow-dependent, and with reduced portal flow in cirrhosis, clearance falls proportionally. Half-life is prolonged.

Third, active metabolite accumulation is a concern. Morphine-6-glucuronide is the active metabolite with analgesic potency 50-100 times morphine itself. While glucuronidation is relatively preserved in cirrhosis, if there's concurrent renal dysfunction—which is common in advanced cirrhosis—M6G accumulates and can cause prolonged sedation and respiratory depression.

Fourth, protein binding changes are relevant. Morphine is only about 30% albumin-bound, so hypoalbuminaemia has less impact compared to highly bound drugs, but there may be a slight increase in free fraction.

My dosing approach would be:

• Reduce the initial dose by 50%
• Extend the dosing interval—perhaps every 6-8 hours instead of every 4 hours
• Use IV rather than oral route for better control
• Consider alternative opioids like fentanyl, which has fewer active metabolites and is less affected by renal dysfunction
• Monitor closely for sedation and respiratory depression
• Use the lowest effective dose

---

Examiner: Thank you. That completes this station.

---

Viva Scenario 2: Acute Liver Failure and Hepatic Encephalopathy

Setting: First Part Physiology Viva. You are presented with a clinical scenario of a patient with acute liver failure and asked to discuss the underlying physiology.

---

Examiner: A 25-year-old woman presents 48 hours after a paracetamol overdose with INR 5.8, pH 7.28, bilirubin 95 μmol/L, and Grade II encephalopathy. Describe the pathophysiology of the coagulopathy.

Candidate: The coagulopathy in acute liver failure reflects severe impairment of hepatic synthetic function combined with the short half-lives of clotting factors.

The liver synthesises all coagulation factors except Factor VIII and von Willebrand factor, which are produced by endothelial cells. The vitamin K-dependent factors—II, VII, IX, and X—as well as Protein C and Protein S, are particularly relevant.

Factor VII has the shortest half-life at 4-6 hours, so it's the first to fall in acute synthetic failure. Since the PT/INR primarily reflects Factor VII activity, it becomes abnormal early and is sensitive to acute hepatic dysfunction. Her INR of 5.8 indicates Factor VII levels are critically low—probably below 10% of normal.

Factor V is also relevant because it's not vitamin K-dependent. Its half-life is 12-36 hours. If Factor V is also low, this confirms synthetic failure rather than just vitamin K deficiency. In the King's College Criteria for non-paracetamol ALF, and the Clichy criteria, Factor V less than 20-30% predicts poor prognosis.

Importantly, acute liver failure creates a "balanced haemostasis" state. The liver also synthesises anticoagulant factors—Protein C, Protein S, and antithrombin. These are equally reduced, so despite the elevated INR suggesting a bleeding tendency, patients may actually be at risk of thrombosis. The INR doesn't reflect this balance. Thromboelastography or ROTEM provides a more accurate picture of haemostatic competence.

The acidosis she has, with pH 7.28, further impairs coagulation factor function. Acidosis reduces the activity of several clotting factors and contributes to platelet dysfunction.

---

Examiner: Explain the pathophysiology of hepatic encephalopathy in acute liver failure.

Candidate: Hepatic encephalopathy in acute liver failure differs from chronic liver disease in its rapidity and severity, with a much higher risk of cerebral oedema.

The central mechanism is hyperammonaemia. In acute liver failure, there's a sudden loss of urea cycle capacity in Zone 1 hepatocytes. Ammonia, produced mainly by gut bacteria and amino acid deamination, cannot be converted to urea and accumulates in blood. Levels can exceed 150-200 μmol/L—more than 3-4 times normal.

Ammonia crosses the blood-brain barrier freely and is taken up by astrocytes, which contain glutamine synthetase. Astrocytes convert ammonia to glutamine: glutamate plus ammonia becomes glutamine. Glutamine is an osmolyte, and as it accumulates intracellularly, water follows by osmosis, causing astrocyte swelling.

In chronic liver disease, astrocytes adapt by extruding other osmolytes—myo-inositol, taurine, and betaine—to maintain cell volume. This compensation takes days to weeks. In acute liver failure, there's insufficient time for this adaptation, so astrocyte swelling progresses rapidly to frank cerebral oedema. This occurs in 50-80% of patients with Grade IV encephalopathy and is the leading cause of death in hyperacute ALF.

Additional mechanisms contribute to neurotoxicity:

• Oxidative stress: Glutamine enters mitochondria and is converted back to glutamate and ammonia, causing mitochondrial dysfunction and reactive oxygen species generation
• Altered neurotransmission: Astrocyte swelling impairs glutamate uptake and release, disrupting the glutamate-glutamine cycle
• GABA-ergic tone: Increased GABA-ergic neurotransmission and endogenous benzodiazepine-like compounds contribute to sedation
• Inflammatory synergy: Systemic inflammation—common in paracetamol toxicity—amplifies ammonia's neurotoxic effects through pro-inflammatory cytokines
• Cerebral hyperaemia: Loss of autoregulation with increased cerebral blood flow can worsen intracranial pressure

---

Examiner: What are the metabolic consequences of acute liver failure relevant to intensive care?

Candidate: Acute liver failure causes multiple metabolic derangements that require ICU-level support.

Hypoglycaemia is common and potentially life-threatening. The liver normally maintains blood glucose through glycogenolysis and gluconeogenesis. In ALF, glycogen stores may already be depleted, and gluconeogenic enzymes are impaired. There's also reduced clearance of insulin, causing relative hyperinsulinaemia. Hypoglycaemia can be refractory and is a poor prognostic sign. Management requires continuous dextrose infusion—typically D10W at 100-150 mL/hour—with frequent blood glucose monitoring, sometimes hourly.

Lactic acidosis occurs through two mechanisms: reduced hepatic lactate clearance—the liver normally metabolises 50-70% of circulating lactate via gluconeogenesis—and increased lactate production from tissue hypoperfusion due to the hyperdynamic circulatory failure seen in ALF. Lactate greater than 3.5 mmol/L after fluid resuscitation is one of the King's College Criteria for poor prognosis.

Hypophosphataemia is common during the regenerative phase. Regenerating hepatocytes have high ATP requirements and take up phosphate avidly. Phosphate levels can fall dramatically and require aggressive replacement. Conversely, persistent hyperphosphataemia suggests failure of regeneration and poor prognosis.

Hyponatraemia results from impaired free water excretion due to non-osmotic ADH release and the hyperdynamic circulation with arterial underfilling. Hyponatraemia compounds cerebral oedema by further reducing plasma osmolality and increasing the osmotic gradient into brain cells.

Respiratory alkalosis is common early, driven by central hyperventilation from ammonia's effect on the brainstem. Later, metabolic acidosis predominates if circulatory failure develops.

---

Examiner: When would you consider this patient for liver transplantation?

Candidate: I would apply the King's College Criteria for paracetamol-induced acute liver failure to assess transplant requirement.

For paracetamol ALF, transplantation is indicated if:

• Arterial pH <7.3 after adequate fluid resuscitation

OR all three of:

• INR >6.5 (or PT >100 seconds)
• Creatinine >300 μmol/L
• Grade III-IV encephalopathy

This patient has pH 7.28, which meets the standalone criterion. She already meets criteria for transplant listing based on the pH alone. However, I would want to ensure this is after adequate resuscitation—if she's volume-depleted or in early shock, the acidosis may improve with fluid resuscitation and vasopressor support.

Her INR of 5.8 approaches but doesn't quite meet the INR criterion of >6.5. Her encephalopathy is Grade II, not Grade III-IV. We don't have her creatinine in this scenario.

Other poor prognostic markers I'd look for include:

• Lactate >3.0 mmol/L after resuscitation
• Phosphate rising (suggests failed regeneration)
• Factor V <10-20%
• Worsening encephalopathy despite treatment
• Arterial ammonia >150 μmol/L with rising trajectory

Early contact with the liver transplant unit is essential because listing decisions take time, donor organ availability is unpredictable, and patients can deteriorate rapidly. In Australia, I would contact the nearest transplant centre immediately for advice and potential transfer, even if criteria aren't yet fully met.

---

Examiner: Thank you. That completes this station.

---

References

1. Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol. 1985;249(5 Pt 1):G549-56. PMID: 3904482

2. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol. 2010;16(48):6046-57. PMID: 21182219

3. Lautt WW. The hepatic artery buffer response: mechanism and clinical implications. Can J Physiol Pharmacol. 2007;85(6):544-52. PMID: 17883559

4. Gulberg V, Haag K, Rossle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology. 2002;35(3):630-4. PMID: 11870377

5. Rappaport AM. The microcirculatory hepatic unit. Microvasc Res. 1973;6(2):212-28. PMID: 4586575

6. Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev. 1989;69(3):708-64. PMID: 2664826

7. Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4):1023-37. PMID: 26116792

8. Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177-97. PMID: 24692138

9. Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016;48:e218. PMID: 26964835

10. Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211-9. PMID: 15915465

11. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-56. PMID: 21751907

12. Butterworth RF. Hepatic encephalopathy: a central neuroinflammatory disorder? Hepatology. 2011;53(4):1372-6. PMID: 21480337

13. Oja SS, Saransaari P, Korpi ER. Neurotoxicity of ammonia. Neurochem Res. 2017;42(3):713-20. PMID: 27804059

14. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. PMID: 23333322

15. Testa B, Krämer SD. The biochemistry of drug metabolism—an introduction: part 1. Principles and overview. Chem Biodivers. 2006;3(10):1053-101. PMID: 17193224

16. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973;1(2):123-36. PMID: 4764426

17. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin Pharmacokinet. 1995;29(5):370-91. PMID: 8582120

18. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83(2):633-71. PMID: 12663868

19. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009;50(12):2340-57. PMID: 19498215

20. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev. 1971;51(1):23-65. PMID: 5543903

21. Lautt WW. Hepatic Circulation: Physiology and Pathophysiology. San Rafael: Morgan & Claypool Life Sciences; 2009. PMID: 21634067

22. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1(4):325-37. PMID: 4056346

23. Lutz J, Henrich H, Bauereisen E. Oxygen supply and uptake in the liver and the intestine. Pflügers Arch. 1975;360(1):7-15. PMID: 1239426

24. Mathie RT, Blumgart LH. Hepatic blood flow: measurement and relationship to liver function. Dig Surg. 1983;2:77-94.

25. Kelly DM, Demetris AJ. The role of the hepatic artery buffer response in liver transplantation. Liver Transpl. 2017;23(11):1450-8. PMID: 28731619

26. Sato N, Eguchi H, Inoue A, et al. Hepatic hemodynamics in patients with chronic liver diseases. Tohoku J Exp Med. 1983;141 Suppl:459-67. PMID: 6680499

27. Rasmussen A, Skak C, Kristensen M, et al. Hepatic hemodynamics during liver transplantation in pigs. Transplant Proc. 1995;27(1):318-20. PMID: 7878999

28. Richardson PD, Withrington PG. Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology. 1981;81(1):159-73. PMID: 7016658

29. Greenway CV, Lautt WW. Hepatic circulation. In: Handbook of Physiology. The Gastrointestinal System. American Physiological Society, Bethesda. 1989;4:1519-64.

30. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis. 1999;19(4):383-96. PMID: 10643624

31. Shah V, Haddad FG, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest. 1997;100(11):2923-30. PMID: 9389760

32. MacSween RNM, Burt AD, Portmann BC, et al. Pathology of the Liver. 5th ed. Churchill Livingstone; 2007.

33. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology. 2000;31(2):255-60. PMID: 10655244

34. Gumucio JJ, Miller DL. Functional implications of liver cell heterogeneity. Gastroenterology. 1981;80(2):393-403. PMID: 7004878

35. Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147-R1151. PMID: 29112863

36. Kietzmann T. Metabolic zonation of the liver: The oxygen gradient revisited. Redox Biol. 2017;11:622-30. PMID: 28126520

37. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1(1):1. PMID: 12437787

38. Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 2017;66(1):212-27. PMID: 27423426

39. Wisse E, Braet F, Luo D, et al. Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol. 1996;24(1):100-11. PMID: 8839287

40. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125-72. PMID: 18195085

41. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26(10):1175-86. PMID: 17105582

42. Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver. Compr Physiol. 2013;3(2):785-97. PMID: 23720329

43. Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4):1023-37. PMID: 26116792

44. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13(10):572-87. PMID: 28731034

45. Nordlie RC, Foster JD, Lange AJ. Regulation of glucose production by the liver. Annu Rev Nutr. 1999;19:379-406. PMID: 10448530

46. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414(1):1-18. PMID: 18651836

47. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382-91. PMID: 11213896

48. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol. 1992;54:885-909. PMID: 1562196

49. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6(9):542-53. PMID: 19652652

50. Evans TW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16 Suppl 5:6-11. PMID: 12423448

51. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85(4):599-610. PMID: 11064620

52. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385-401. PMID: 3281888

53. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med. 2010;5(1):7-12. PMID: 19949895

54. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273-5. PMID: 8101303

55. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-54. PMID: 9971870

56. Nguyen P, Leray V, Diez M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl). 2008;92(3):272-83. PMID: 18477307

57. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):99-109. PMID: 25815989

58. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-31. PMID: 11994399

59. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169-96. PMID: 15102878

60. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395-420. PMID: 6157353

61. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25(2):262-84. PMID: 28178565

62. Häussinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J. 1990;267(2):281-90. PMID: 2185738

63. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87-105. PMID: 12055339

64. Meijer AJ, Lamers WH, Chamuleau RA. Nitrogen metabolism and ornithine cycle function. Physiol Rev. 1990;70(3):701-48. PMID: 2194222

65. Häussinger D. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem. 1983;133(2):269-75. PMID: 6861744

66. Butterworth RF, Norenberg MD, Felipo V, et al. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int. 2009;29(6):783-8. PMID: 19638106

67. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360(9340):1155-62. PMID: 12387968

68. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008;21(1):70-83. PMID: 18052394

69. Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004;32(11):1201-8. PMID: 15304429

70. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376-82. PMID: 24458010

71. Testa B, Krämer SD. The biochemistry of drug metabolism—an introduction: part 2. Redox reactions and their enzymes. Chem Biodivers. 2007;4(3):257-405. PMID: 17372941

72. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581-616. PMID: 10836148

73. Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(2):103-16. PMID: 20668491

74. Pond SM, Tozer TN. First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet. 1984;9(1):1-25. PMID: 6362950

75. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880-6. PMID: 16467132

76. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147-61. PMID: 18762933

77. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377-90. PMID: 1164821

78. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Lippincott Williams & Wilkins; 2011.

79. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115-21. PMID: 11907485

80. Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3(3):1035-78. PMID: 23897680

81. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-74. PMID: 12543708

82. Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci (Landmark Ed). 2009;14:2584-98. PMID: 19273221

83. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461-83. PMID: 18488143

84. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol. 2011;(201):205-59. PMID: 21103971

85. Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos. 2014;42(4):561-5. PMID: 24459177

86. Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28(5):592-605. PMID: 18433389

87. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003;38(1):107-17. PMID: 12480568

88. Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013;19(38):6398-407. PMID: 24151358

89. Keppler D. Cholestasis and the role of basolateral efflux pumps. Z Gastroenterol. 2011;49(12):1553-7. PMID: 22161712

90. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology. 2014;146(7):1625-38. PMID: 24704527

91. Kadakol A, Ghosh SS, Sappal BS, et al. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat. 2000;16(4):297-306. PMID: 11013440

92. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333(18):1171-5. PMID: 7565971

93. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648-51. PMID: 3732997

94. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-21. PMID: 11870389

95. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015;62(2):437-47. PMID: 25218789

96. Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis. 2005;20(4):303-18. PMID: 16382342

97. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57(8):1156-65. PMID: 18628376

98. Butterworth RF. The neurobiology of hepatic encephalopathy. Semin Liver Dis. 1996;16(3):235-44. PMID: 8989809

99. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22(1):125-38. PMID: 17260161

100. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-35. PMID: 25042402

101. Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. PMID: 27089005

102. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81. PMID: 20335583

103. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350—electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174(11):1727-33. PMID: 25243839

104. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-45. PMID: 2490426

105. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376(9736):190-201. PMID: 20638564

106. Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol. 2012;56(1):129-36. PMID: 21703173

107. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-52. PMID: 17685471

108. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-9. PMID: 16315313

109. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32(4 Pt 1):734-9. PMID: 11003617

110. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-34. PMID: 24369077

111. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11(1):49-53. PMID: 2295470

112. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-63. PMID: 11867109

113. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-71. PMID: 10733541

114. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-26. PMID: 18768945

115. Bosch J, Garcia-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(1 Suppl):141-56. PMID: 10728801

116. Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology. 2015;61(4):1406-15. PMID: 25092403

117. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121-31. PMID: 16447289

118. Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-8. PMID: 17389705

119. Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100(7):1440-52. PMID: 27326810

120. Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology. 2001;34(6):1103-8. PMID: 11731997

121. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study. Lancet. 2016;388(10040):131-57. PMID: 27108232

122. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. End-stage renal disease in indigenous Australians: a disease of disadvantage. Ethn Dis. 2002;12(3):373-8. PMID: 12148707

123. Alexander GJ, O'Grady JG, Rolando N, et al. Assessment of hepatic function. In: Holstege A, Bianchi L, editors. Liver and Nervous System. Springer; 1989.

124. Pilcher D, Bailey M, Warrillow S, Bellomo R. Intensive care services for liver failure in Australia and New Zealand. Crit Care Resusc. 2012;14(2):119-24. PMID: 22697619